Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients

A Prospective Cohort Study

Fabrizio Fabrizi, Antonio Tarantino, Claudia Castelnovo, Paul Martin, Pier Giorgio Messa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background/Aims: Patients undergoing maintenance dialysis have an unsatisfactory response to vaccination, including to hepatitis B vaccine. A recombinant HB vaccine containing a new adjuvant system AS04 (HBV-AS04) has been recently developed; a few data exist on the immunogenicity and safety of HBV-AS04 among patients undergoing regular dialysis. All hepatitis B virus-seronegative patients with undetectable antibody against HBsAg undergoing maintenance dialysis at two units were prospectively included. Methods: Patients received four 20-mcg doses of HBV-AS04 by intramuscular route (deltoid muscle) at months 0,1,2, and 3. Anti-HB surface antibody concentrations were measured at intervals of 1, 2, 3, 4, and 12 months. Univariate and multivariate analyses determined which parameters predicted immunologic response to HBV-AS04 vaccine. Results: 102 patients were enrolled and 91 completed the study. At completion of the vaccination schedule, using per-protocol analysis, 76 of 91 (84%) had antibody titers ≥10 mIU/mL with anti-HBs geometric antibody concentrations (GMCs) of 385.25 mIU/mL. The sero-protection rate at month 12 was 84% (48/57) with lower GMCs (62.74 mIU/mL, P<0.0001). Multivariate analysis revealed a detrimental role of age on the immune response to HB-AS04 vaccine (F Ratio, 4.04; P<0.04). Tolerance to HBV-AS04 was good and only minor side-effects were observed. Conclusions: HBV-AS04 vaccine was highly immunogenic in our cohort of patients on maintenance dialysis even if a significant number of non-responders is still present. Prospective studies with HBV-AS04 on larger study groups and with longer follow-ups are under way.

Original languageEnglish (US)
Pages (from-to)584-592
Number of pages9
JournalKidney and Blood Pressure Research
Volume40
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

Hepatitis B Vaccines
Synthetic Vaccines
Dialysis
Cohort Studies
Prospective Studies
Antibodies
Maintenance
Vaccination
Multivariate Analysis
Deltoid Muscle
Hepatitis B Surface Antigens
Hepatitis B virus
Appointments and Schedules
Vaccines
Safety

Keywords

  • Adjuvant
  • Dialysis
  • Hepatitis B vaccine
  • Immunogenicity
  • Safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Nephrology

Cite this

Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients : A Prospective Cohort Study. / Fabrizi, Fabrizio; Tarantino, Antonio; Castelnovo, Claudia; Martin, Paul; Messa, Pier Giorgio.

In: Kidney and Blood Pressure Research, Vol. 40, No. 6, 01.12.2015, p. 584-592.

Research output: Contribution to journalArticle

Fabrizi, Fabrizio ; Tarantino, Antonio ; Castelnovo, Claudia ; Martin, Paul ; Messa, Pier Giorgio. / Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients : A Prospective Cohort Study. In: Kidney and Blood Pressure Research. 2015 ; Vol. 40, No. 6. pp. 584-592.
@article{ec6c2d5aef0a4ea8b9fc06cd4db958c2,
title = "Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study",
abstract = "Background/Aims: Patients undergoing maintenance dialysis have an unsatisfactory response to vaccination, including to hepatitis B vaccine. A recombinant HB vaccine containing a new adjuvant system AS04 (HBV-AS04) has been recently developed; a few data exist on the immunogenicity and safety of HBV-AS04 among patients undergoing regular dialysis. All hepatitis B virus-seronegative patients with undetectable antibody against HBsAg undergoing maintenance dialysis at two units were prospectively included. Methods: Patients received four 20-mcg doses of HBV-AS04 by intramuscular route (deltoid muscle) at months 0,1,2, and 3. Anti-HB surface antibody concentrations were measured at intervals of 1, 2, 3, 4, and 12 months. Univariate and multivariate analyses determined which parameters predicted immunologic response to HBV-AS04 vaccine. Results: 102 patients were enrolled and 91 completed the study. At completion of the vaccination schedule, using per-protocol analysis, 76 of 91 (84{\%}) had antibody titers ≥10 mIU/mL with anti-HBs geometric antibody concentrations (GMCs) of 385.25 mIU/mL. The sero-protection rate at month 12 was 84{\%} (48/57) with lower GMCs (62.74 mIU/mL, P<0.0001). Multivariate analysis revealed a detrimental role of age on the immune response to HB-AS04 vaccine (F Ratio, 4.04; P<0.04). Tolerance to HBV-AS04 was good and only minor side-effects were observed. Conclusions: HBV-AS04 vaccine was highly immunogenic in our cohort of patients on maintenance dialysis even if a significant number of non-responders is still present. Prospective studies with HBV-AS04 on larger study groups and with longer follow-ups are under way.",
keywords = "Adjuvant, Dialysis, Hepatitis B vaccine, Immunogenicity, Safety",
author = "Fabrizio Fabrizi and Antonio Tarantino and Claudia Castelnovo and Paul Martin and Messa, {Pier Giorgio}",
year = "2015",
month = "12",
day = "1",
doi = "10.1159/000368534",
language = "English (US)",
volume = "40",
pages = "584--592",
journal = "Kidney and Blood Pressure Research",
issn = "1420-4096",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients

T2 - A Prospective Cohort Study

AU - Fabrizi, Fabrizio

AU - Tarantino, Antonio

AU - Castelnovo, Claudia

AU - Martin, Paul

AU - Messa, Pier Giorgio

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background/Aims: Patients undergoing maintenance dialysis have an unsatisfactory response to vaccination, including to hepatitis B vaccine. A recombinant HB vaccine containing a new adjuvant system AS04 (HBV-AS04) has been recently developed; a few data exist on the immunogenicity and safety of HBV-AS04 among patients undergoing regular dialysis. All hepatitis B virus-seronegative patients with undetectable antibody against HBsAg undergoing maintenance dialysis at two units were prospectively included. Methods: Patients received four 20-mcg doses of HBV-AS04 by intramuscular route (deltoid muscle) at months 0,1,2, and 3. Anti-HB surface antibody concentrations were measured at intervals of 1, 2, 3, 4, and 12 months. Univariate and multivariate analyses determined which parameters predicted immunologic response to HBV-AS04 vaccine. Results: 102 patients were enrolled and 91 completed the study. At completion of the vaccination schedule, using per-protocol analysis, 76 of 91 (84%) had antibody titers ≥10 mIU/mL with anti-HBs geometric antibody concentrations (GMCs) of 385.25 mIU/mL. The sero-protection rate at month 12 was 84% (48/57) with lower GMCs (62.74 mIU/mL, P<0.0001). Multivariate analysis revealed a detrimental role of age on the immune response to HB-AS04 vaccine (F Ratio, 4.04; P<0.04). Tolerance to HBV-AS04 was good and only minor side-effects were observed. Conclusions: HBV-AS04 vaccine was highly immunogenic in our cohort of patients on maintenance dialysis even if a significant number of non-responders is still present. Prospective studies with HBV-AS04 on larger study groups and with longer follow-ups are under way.

AB - Background/Aims: Patients undergoing maintenance dialysis have an unsatisfactory response to vaccination, including to hepatitis B vaccine. A recombinant HB vaccine containing a new adjuvant system AS04 (HBV-AS04) has been recently developed; a few data exist on the immunogenicity and safety of HBV-AS04 among patients undergoing regular dialysis. All hepatitis B virus-seronegative patients with undetectable antibody against HBsAg undergoing maintenance dialysis at two units were prospectively included. Methods: Patients received four 20-mcg doses of HBV-AS04 by intramuscular route (deltoid muscle) at months 0,1,2, and 3. Anti-HB surface antibody concentrations were measured at intervals of 1, 2, 3, 4, and 12 months. Univariate and multivariate analyses determined which parameters predicted immunologic response to HBV-AS04 vaccine. Results: 102 patients were enrolled and 91 completed the study. At completion of the vaccination schedule, using per-protocol analysis, 76 of 91 (84%) had antibody titers ≥10 mIU/mL with anti-HBs geometric antibody concentrations (GMCs) of 385.25 mIU/mL. The sero-protection rate at month 12 was 84% (48/57) with lower GMCs (62.74 mIU/mL, P<0.0001). Multivariate analysis revealed a detrimental role of age on the immune response to HB-AS04 vaccine (F Ratio, 4.04; P<0.04). Tolerance to HBV-AS04 was good and only minor side-effects were observed. Conclusions: HBV-AS04 vaccine was highly immunogenic in our cohort of patients on maintenance dialysis even if a significant number of non-responders is still present. Prospective studies with HBV-AS04 on larger study groups and with longer follow-ups are under way.

KW - Adjuvant

KW - Dialysis

KW - Hepatitis B vaccine

KW - Immunogenicity

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84983196090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983196090&partnerID=8YFLogxK

U2 - 10.1159/000368534

DO - 10.1159/000368534

M3 - Article

VL - 40

SP - 584

EP - 592

JO - Kidney and Blood Pressure Research

JF - Kidney and Blood Pressure Research

SN - 1420-4096

IS - 6

ER -